diff --git a/domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md b/domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md index f043cd2b..757a6344 100644 --- a/domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md +++ b/domains/health/federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md @@ -39,6 +39,12 @@ The GLP-1 case is particularly stark because the clinical evidence is robust (ca The claim that budget scoring "systematically" undervalues prevention requires evidence beyond a single case. However, the GLP-1 divergence is consistent with known CBO methodology (10-year window, conservative assumptions) and parallels similar scoring challenges for other preventive interventions (vaccines, screening programs). The structural bias is well-documented in health policy literature, though this source provides the most dramatic single-case illustration. + +### Additional Evidence (confirm) +*Source: [[2024-11-01-aspe-medicare-anti-obesity-medication-coverage]] | Added: 2026-03-16* + +The CBO vs. ASPE divergence on Medicare GLP-1 coverage provides concrete evidence: CBO projects $35B in additional spending (2026-2034) using budget scoring methodology, while ASPE projects net savings of $715M over 10 years using clinical economics methodology that includes downstream event avoidance. The $35.7B gap between these estimates demonstrates how budget scoring rules structurally disadvantage preventive interventions. CBO uses conservative uptake assumptions and doesn't fully count avoided hospitalizations and disease progression within the 10-year window, while ASPE includes 38,950 CV events avoided and 6,180 deaths avoided. Both are technically correct but answer different questions—budget impact vs. clinical economics. + --- Relevant Notes: diff --git a/inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md b/inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md index 23455543..6d6b73a1 100644 --- a/inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md +++ b/inbox/archive/2024-11-01-aspe-medicare-anti-obesity-medication-coverage.md @@ -7,9 +7,13 @@ date: 2024-11-01 domain: health secondary_domains: [internet-finance] format: policy -status: unprocessed +status: enrichment priority: medium tags: [glp-1, medicare, obesity, budget-impact, CBO, federal-spending] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,12 @@ WHY ARCHIVED: The CBO vs. ASPE divergence reveals a systematic bias in how preve EXTRACTION HINT: Focus on the methodological divergence as evidence of structural misalignment in policy evaluation, not just the GLP-1 budget numbers flagged_for_leo: ["Budget scoring methodology systematically disadvantages prevention — this is a cross-domain structural problem affecting all preventive health investments"] + + +## Key Facts +- CBO estimates Medicare coverage of anti-obesity medications would increase federal spending by $35 billion over 2026-2034 +- ASPE estimates net savings of $715 million over 10 years from Medicare GLP-1 coverage (range: $412M to $1.04B) +- Broad semaglutide access projected to avoid 38,950 CV events and 6,180 deaths over 10 years +- Annual Part D cost increase from Medicare GLP-1 coverage: $3.1-6.1 billion +- Approximately 10% of Medicare beneficiaries would be eligible under proposed criteria requiring comorbidities +- Proposed eligibility criteria require CVD history, heart failure, CKD, or prediabetes—not just BMI threshold